The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications
about
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradationMechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pHDegradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularlyThe proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2Self-association of human PCSK9 correlates with its LDLR-degrading activityAnnexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levelsThe PCSK9 decadeNew developments in atherosclerosis: clinical potential of PCSK9 inhibitionHypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesCholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemiaMolecular biology of PCSK9: its role in LDL metabolismStructural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemiaMolecular basis for LDL receptor recognition by PCSK9In vivo evidence that furin from hepatocytes inactivates PCSK9The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functionsPhysiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cellsTrans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained.Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)Modulation of protease activated receptor 1 influences human metapneumovirus disease severity in a mouse modelPCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9.High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levelsOn the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expressionPlasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.Autosomal dominant hypercholesterolemia: needs for early diagnosis and cascade screening in the tunisian population.Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study.PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.PCSK9 Association With Lipoprotein(a)
P2860
Q24294486-B334F823-E8D0-493A-93A6-7B3C4BD5CFAFQ24297165-A28ACE8B-0F78-463B-A4F1-F294909D7913Q24298534-AF6D5326-9116-4180-993E-7B0FF2F9664DQ24301411-68BAE013-DA5C-440E-AB7A-832437629333Q24306591-8C6A8868-4070-47F6-B5B4-F3E53D6F9749Q24313575-B33C0913-02D7-4FE8-9F92-314DFB4D10C9Q24615397-CF191B26-8E8D-4C36-9C0A-2AA871D60CEFQ26783407-379D66FF-EFAC-47AE-B4CE-728D06F201F3Q26786549-B7C57156-D855-49F0-934C-137C835DF3F5Q27009477-E55DDB75-9E53-4B0A-8609-1499F07B720CQ27013494-A86EEFED-3024-4E8D-96BC-BB409AED05C6Q27488922-96F12FD5-1CE0-4C02-8CEA-E269CF8BD16AQ27644461-0DFBC769-2030-4CFD-9405-C1292E5902A7Q27649779-680FFFEB-9DF5-40EF-9DBF-C46B69D0BA1CQ28504537-21832363-8CB1-4778-AEAC-834B55410323Q30541820-AD55207A-B5C5-4FBD-85A4-2BDDE76E6C6CQ33599961-586A533F-C817-4769-A5F8-46D20C409143Q34227474-6C0E09E9-9630-4197-B1AF-0165568F37D8Q34306545-CD7F427C-8841-4141-9ABA-2DB306B9E434Q34430377-7CAA4D04-C9B5-4A6A-8F17-70729A729376Q34433146-7A79DACC-A5EE-4FE7-9DC8-DD03682CB7B7Q34458693-04A9DBBD-1949-4040-89D9-228E955C5890Q34536594-F5931C85-45FF-4E5C-9FC1-F4CCD2735902Q34560763-E74DD72F-C584-4084-BAF2-72222A517EC2Q34649888-102A10F0-C6F6-45A4-BD85-453170DCEF3FQ34723257-F1F491A6-8C70-4C51-A778-25CE709723F1Q34981539-EF274100-B0B7-4F5C-9FD1-A938C45AC633Q35262593-08A21E38-F041-40FE-8B82-3EB7DD8B586DQ35911079-4ED9BB79-A364-4C26-8A96-DA5E8F9C30C0Q36035643-872883D5-BB49-4A0D-A0F5-B501A7A57480Q36078804-E50AF2DA-98F9-45BA-910A-8662CF6C534CQ36281706-62D08B04-D634-4CBE-82F6-E47F7BABBE30Q36481769-938F930E-FE97-47BB-88DC-29781ECAFD9BQ36574008-50590FF0-EC50-422F-82A6-49C7D3BE5A91Q36634114-44719056-54CF-4BF5-AB22-FCAE1B1C86BBQ36708550-8C8C465B-331A-4869-8594-D809747D191DQ36812669-20C78B90-C384-4070-90D9-DE9BB6F4955EQ36854525-32C81A15-2E63-4C0F-8C21-E20E9CD8268EQ36862604-F3F1C1B0-FE11-46B1-8F05-9301FE565939Q37037349-48EFBB8D-6425-475C-AE68-31ACA638BB0A
P2860
The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The proprotein convertase (PC) ...... st-translational modifications
@ast
The proprotein convertase (PC) ...... st-translational modifications
@en
The proprotein convertase (PC) ...... st-translational modifications
@en-gb
The proprotein convertase (PC) ...... st-translational modifications
@nl
type
label
The proprotein convertase (PC) ...... st-translational modifications
@ast
The proprotein convertase (PC) ...... st-translational modifications
@en
The proprotein convertase (PC) ...... st-translational modifications
@en-gb
The proprotein convertase (PC) ...... st-translational modifications
@nl
prefLabel
The proprotein convertase (PC) ...... st-translational modifications
@ast
The proprotein convertase (PC) ...... st-translational modifications
@en
The proprotein convertase (PC) ...... st-translational modifications
@en-gb
The proprotein convertase (PC) ...... st-translational modifications
@nl
P2093
P2860
P921
P356
P1476
The proprotein convertase (PC) ...... st-translational modifications
@en
P2093
David Rhainds
Josée Hamelin
Nasha Nassoury
Suzanne Benjannet
P2860
P304
P356
10.1074/JBC.M606495200
P407
P577
2006-10-13T00:00:00Z